Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 18, 2019
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFICJhanelle E Gray, Augusto Villegas, Davey Daniel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 StudyEdward B Garon, Matthew D Hellmann, Naiyer A Rizvi, et al.
JTO Clinical and Research Reports|October 15, 2025
Corrigendum to "Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC [JTO Clinical and Research Reports Vol. 4 No. 1: 100431]Marina C Garassino, Shirish Gadgeel, Silvia Novello, et al.
The New England Journal of Medicine|September 16, 2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast CancerPeter Schmid, Javier Cortes, Rebecca Dent, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2023
Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 StudyMarina C Garassino, Shirish Gadgeel, Giovanna Speranza, et al.
Breast Cancer Research and Treatment|December 2, 2021
Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testingPhuong Dinh, J Dinny Graham, Elisabeth N Elder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 18, 2019
Lucitanib for the Treatment of HR<sup>+</sup>/HER2<sup>-</sup> Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE StudyRina Hui, Alex Pearson, Javier Cortes, et al.
Nature Medicine|January 21, 2025
Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trialFatima Cardoso, Joyce O'Shaughnessy, Zhenzhen Liu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung CancerDavid R Spigel, Corinne Faivre-Finn, Jhanelle E Gray, et al.
Pageof 9